Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro

Overview of attention for article published in American Journal of Obstetrics & Gynecology, August 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Above-average Attention Score compared to outputs of the same age and source (56th percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 15,287 followers.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine serous pap… http://t.co/P5Y0ouKUNx

Gynecology News: Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against prima... http://t.co/sbuCyBTzQp

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.